Hørsholm, Denmark, March 30, 2017 – Today, ExpreS2ion Biotech Holding AB announces that the fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) has received the final approval of a Consortium Agreement together with Abera Bioscience AB and the University of Copenhagen, for a Eurostars grant for the project named ‘OptiFemVac’. The approval of the Consortium Agreement triggers a grant of approx. EUR 750,000 of which ExpreS2ion expects to receive approx. EUR 300,000. The approval follows the initial approval which ExpreS2ion Biotech Holding AB communicated in a press release on January 23, 2017.
The OptiFemVac project
The aim of the Consortium is to develop new vaccines for female reproductive and infant health. The Consortium combines special delivery platforms based on both virus and bacteria, which potentially enable superior, long-lasting and cost effective vaccines. The main focus of the OptiFemVac project is the development of a Zika vaccine, but the potential for a combined Human Papilloma Virus (HPV) and Placental Malaria (PM) vaccine will be also be addressed. The Consortium plans to have proof of concept in animals within one year from initiation of the work.
The Eurostars grant
The Consortium’s grant application is approved under the project name OptiFemVac (see https://www.eurostars-eureka.eu/project/id/11019) with ExpreS2ion as project lead. The overall project budget amounts to EUR 1.6M, which covers a period of 36 months. The awarded grant is approx. EUR 750,000 of which ExpreS2ion can expect to receive approx. EUR 300,000. According to the approved Consortium Agreement, ExpreS2ion’s activities will be initiated immediately and mainly take place in 2017 and the funding will thus be recognised in the fiscal year 2017.
Abera Bioscience AB
Abera Bioscience AB is a private Swedish biotech company, which has developed a new and unique platform for vaccine enhancement and delivery of vaccines. The core element is Outer Membrane Vesicles (OMVs) that can deliver multiple antigens of choice at a high density. Additional information about Abera can be found on www.aberabio.com.
University of Copenhagen
The Centre for Medical Parasitology (CMP) is a collaboration between the University of Copenhagen and Rigshospitalet (DK). CMP’s research is focused on malaria and it is part of a well-established international scientific network composed of scientists in Europe, Africa, America and Australia. More than 60 scientists and technicians are affiliated at CMP, for more information see www.cmp.ku.dk/english.
CEO Dr. Steen Klysner comments
“I am very pleased that the Consortium Agreement was approved and that we can initiate the project. The combination of unique front-end technologies held by the Consortium is a very competitive combination for the development of new efficient vaccines against Zika and HPV/malaria. Furthermore, if successful, the applied platform has potential for application in other similar indications, as well as therapeutic vaccines like cancer.”